Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 10.77M -90.0% |
| Revenue (ttm) | 2.50M +287.2% |
| Net Income | -67.62M |
| EPS | -1.66 |
| Shares Out | 44.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 347,157 |
| Open | 0.2462 |
| Previous Close | 0.2462 |
| Day's Range | 0.2425 - 0.2584 |
| 52-Week Range | 0.1980 - 5.1400 |
| Beta | 0.39 |
| Analysts | Hold |
| Price Target | 1.00 (+311.86%) |
| Earnings Date | Aug 14, 2026 |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also deve... [Read more]
Financial Performance
In fiscal year 2026, Vistagen Therapeutics's revenue was $1.27 million, an increase of 161.11% compared to the previous year's $486,000. Losses were -$69.69 million, 35.5% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $1.0, which is an increase of 311.86% from the latest price.
News
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
Vistagen Therapeutics Earnings release: Q1 2027
Vistagen Therapeutics released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Vistagen Therapeutics Quarterly report: Q1 2027
Vistagen Therapeutics has published its Q1 2027 quarterly earnings report on August 14, 2026.
Vistagen announces topline results from fasedienol repeat dose study
Vistagen (VTGN) announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder. The three-arm, multicenter,...
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Pre...
SRX Global acquires stake in Vistagen
SRX Global (SRXH) announced that it has acquired a stake in Vistagen (VTGN). The company said it views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team…
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to dev...
Vistagen Therapeutics Proxy statement: Proxy filing
Vistagen Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Vistagen Therapeutics Proxy statement: Proxy filing
Vistagen Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Vistagen Therapeutics Transcript: Study update
The PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder did not meet primary or secondary endpoints in the overall population, but post-hoc analyses showed significant benefit in patients with very severe anxiety. Plans are underway to pursue a new registrational pathway using LSAS as the primary endpoint, supported by pooled data and favorable safety results.
Vistagen Therapeutics Press release: Study update
Vistagen Therapeutics issued a press release on June 30, 2026, disclosing material business information to investors.
Vistagen announces fasedienol did not achieve primary endpoint
Vistagen (VTGN) announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. In the overall trial population, fasedienol d...
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings release: Q4 2026
Vistagen Therapeutics released its Q4 2026 earnings on June 15, 2026, summarizing the period's financial results.
Vistagen Therapeutics Annual report: Q4 2026
Vistagen Therapeutics has published its Q4 2026 annual report on June 15, 2026.
Vistagen announces fasedienol achieves minimum patient exposures
Vistagen (VTGN) announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended un...
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.
Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The session highlighted advances in intranasal neuroscience candidates, with fasedienol leading in SAD treatment and key phase III data for PALISADE-4 expected soon. Pipeline assets itruvone and refisolone show promise in MDD and menopausal hot flashes, with cash runway into 2027.
Vistagen appoints Angelov as Chief Medical Officer
Vistagen (VTGN) announced the appointment of Angel Angelov, MD, MBA, as Chief Medical Officer, CMO, effective May 18, 2026. Dr. Angelov most recently served as CMO at Theranica Published first…
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new cla...
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
Vistagen (VTGN) announced preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a...
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...